Jay S. Duker
Tracked across 1 events · 22 articles · First seen Aug 21, 2026 · Last active Sep 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
On August 17, 2026, EyePoint Pharmaceuticals announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU (vorolanib intravitreal insert) in wet age-related macular degeneration. The trial failed to meet its prespecified…
Impact: Jay S. Duker, CEO of EyePoint, made optimistic statements about DURAVYU's 'derisked' potential prior to the trial failure, which are now under scrutiny in the investigations.
Aug 21, 2026 · 22 articles
70
Jay S. Duker made confident statementsEyePoint DURAVYU Phase 3...
ERGEN INTELLIGENCE
Track Jay S. Duker live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard